urbanbuzz / Shutterstock.com
Pfizer has apologised to UK-based healthcare providers for any confusion or increased workload following the English High Court’s decision on a patent infringement case centring on its epilepsy drug Lyrica (pregabalin).
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Pfizer, Lyrica, NHS, second medical use patent, Actavis